Sodium-glucose cotransporter 2 inhibitors (eg, dapagliflozin) are understudied in kidney transplant recipients. A trial attempted to fill this knowledge gap.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an additional indication for dapagliflozin (Forxiga ...

Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...

Starting dapagliflozin (Farxiga) early during acute heart failure hospitalization didn't boost decongestion, although it appeared to spare loop diuretic doses and increase diuresis compared with usual ...

In April 2021, dapagliflozin (Farxiga) received a new indication from the US Food and Drug Administration (FDA) for slowing progression of chronic kidney disease (CKD) in people without any other ...

An analysis of the DELIVER trial also revealed an association between dapagliflozin treatment and reduced risk of cardiovascular death among individuals with heart failure with improved ejection ...

Adding an SGLT2 inhibitor to standard care did not improve clinical outcomes in critically ill patients with acute organ dysfunction, an open-label randomized trial involving intensive care units ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...